Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: GlobalData
$125.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Zealand Pharma A/S Announces Sub-Analysis Results from GetGoal-L Phase III Clinical Study on Lyxumia that Is Marketed by Sanofi


Tuesday, 24 Sep 2013 07:37am EDT 

Zealand Pharma A/S announced that new sub-analysis results from the GetGoal-L Phase III clinical study show that reductions in HbA1c with Lyxumia (lixisenatide), when added to basal insulin, were greatest in patients with type 2 diabetes who had well-controlled baseline fasting plasma glucose (FPG). Reductions in body weight with Lyxumia, when added to basal insulin, were also greatest in this group. The new results were presented on September 24, 2013 in an oral session at the 49th Annual Meeting of the European Association for the Study of Diabetes in Barcelona. As noted by Sanofi in a press release, Type 2 diabetes is a progressive disease and patients treated with basal insulin may over time no longer maintain their target HbA1c level (2 to 3 months average blood sugar levels) despite typically sustaining good control of FPG with basal insulin. 

Company Quote

67.5
0.5 +0.75%
11 Jul 2014